MitoSense and Aquila Health Enter Strategic Partnership to Build AI-Ready Data Infrastructure for Mitochondrial Medicine

Built on Aquila's TREUE™ standard, the collaboration will create a governed, longitudinal data foundation for mitochondrial medicine

PLYMOUTH, MA, July 23, 2026 — MitoSense, Inc., a biotechnology company developing therapies that restore function for neurodegenerative, metabolic, and other diseases linked to mitochondrial dysfunction, today announced a strategic partnership with Aquila Health PBC, a healthcare data infrastructure company, to create an artificial intelligence-ready data foundation for its research, future clinical programs, and commercial activities. The collaboration is expected to help researchers better understand disease progression and treatment response in conditions such as ALS, Parkinson's disease, Alzheimer's disease, Long COVID, and HIV.

As MitoSense's strategic partner, Aquila will use its TREUE™ standard to create a governed, complete patient view by connecting fragmented healthcare data across systems. This addresses a central challenge in advanced medicine: researchers cannot fully understand disease progression, treatment response, and long-term outcomes without understanding the whole patient. Despite healthcare generating enormous volumes of data, an estimated 97% goes unused, leaving researchers with incomplete patient records that make it difficult to gain a multi-dimensional understanding of patient health over time. 

For an emerging field such as mitochondrial medicine, this is particularly critical, as patient response may be shaped by medications, therapies, coexisting conditions, organ function, inflammation, metabolism, immune response, and long-term disease progression. For example, if a patient with ALS experiences slower disease progression, or a patient with Alzheimer's disease demonstrates changes in cognitive function during a future clinical study, researchers need to understand whether those outcomes are associated with the investigational therapy or influenced by other medications, underlying conditions, or unrelated clinical factors. Without that context, important signals can be missed or clinical outcomes misinterpreted.

“Mitochondrial medicine will require a new kind of data backbone,” said Van Hipp, Chairman of MitoSense. “We are working in an area where patient history, medications, biomarkers, safety signals, clinical outcomes, and long-term follow-up all matter. To understand whether a patient is improving, stable, or experiencing a setback, we need to understand the whole patient, including what other drugs or therapies may be affecting their health. Aquila brings the governed, AI-ready infrastructure needed to connect those pieces responsibly. This partnership is about making sure the data foundation is ready for the science.”

Rather than requiring healthcare organizations to move sensitive patient information into a centralized repository, Aquila securely connects data where it already resides, allowing researchers to generate insights while organizations maintain control of their data. The companies will continue to evaluate how Aquila's TREUE™ standard and related AI capabilities support MitoSense's clinical research, outcome analytics, data management initiatives, and future project-based engagements. In time, the AI data foundation is expected to help MitoSense identify meaningful biomarkers, monitor safety, and generate the evidence needed to advance development of treatment programs.

Aquila is led by Dr. Jaime Bland, DNP, RN, Co-Founder and Chief Executive Officer. Dr. Bland previously served as President and CEO of CyncHealth, where she helped build and operate a multi-state health information exchange network supporting data coordination across more than six million lives.

“Healthcare does not suffer from a lack of data. It suffers from fragmented data that cannot be used together responsibly,” said Dr. Jaime Bland, Co-Founder and CEO of Aquila Health PBC. “MitoSense is advancing science that will require longitudinal, multi-source evidence across clinical, laboratory, biomarker, medication, and outcome data. Aquila was built to make that kind of data usable, secure, governed, and ready for advanced analytics without forcing organizations into a single centralized warehouse. We are excited to work with MitoSense to explore how our infrastructure can support clinical research, translational science, and future evidence generation.”

MitoSense is currently advancing preclinical and regulatory groundwork towards Phase 1 clinical trials, with Aquila’s AI data infrastructure planned to support future studies though the mitochondrial medicine platform.

About MitoSense

MitoSense, Inc. is a biotechnology company focused on mitochondrial health and mitochondrial organelle transplantation technologies. The company is developing platforms intended to study and address mitochondrial dysfunction across high-impact translational applications, including neurodegenerative disease, post-viral syndromes, and other conditions where impaired cellular energy may play an important role. MitoSense is also building a growing network of scientific, clinical, patient-advocacy, and translational relationships, including collaborations and engagements with James A. Haley Veterans; Hospital, Walter Reed Army Institute of Research (WRAIR) through Cooperative Research and Development, Agreements (CRADAs), Greenwood Genetic Center, and Hop On a Cure. These relationships support MitoSense’s strategy of advancing mitochondrial science through disciplined research partnerships, patient- centered insight, and real-world evidence generation, focused on specific clinical, longevity, or anti-aging outcomes in the future. For more information, please visit: www.mitosense.com.

About Aquila Health PBC

Aquila Health PBC is a Delaware public benefit corporation focused on healthcare data infrastructure, artificial intelligence, information exchange governance, and population health analytics. Its TREUE™ platform is designed to normalize and mobilize fragmented health data across organizations, systems, and geographies, enabling longitudinal, multi-source data integration for research, clinical decision-making, public health, and regulated healthcare environments. For more information, please visit: https://www.aquilahealth.com/.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding potential collaborations, future Master Agreement negotiations, project-based engagements, data infrastructure development, artificial intelligence and machine learning capabilities, clinical research support, mitochondrial health technologies, translational research, and future evidence generation. These statements are based on current expectations and are subject to risks and uncertainties. The Strategic Partnership Memorandum of Understanding described herein is nonbinding except for specified provisions, and specific activities remain subject to negotiation and execution of definitive agreements. No assurance can be given that any collaboration, project, platform deployment, research program, product candidate, diagnostic application, therapeutic application, commercial application, or regulatory use case will be successfully developed, approved, funded, adopted, or commercialized.